Physician profile
Robert A Scalia
NPI 1225021439
$10,471.29
in general payments reported to CMS, 2019-2025
39 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $966 · 2021: $979 · 2022: $1,353 · 2023: $1,820 · 2024: $1,859 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,540 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,539.74 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,337.03 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $1,272.59 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,062.01 | 2019-2025 | |
| Novo Nordisk INC | $914.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $810.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $767.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.33 | 2022-2025 | Caplyta |
| Amgen INC. | $181.02 | 2019-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $139.89 | 2019-2020 | |
| Exact Sciences Corporation | $124.16 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $114.45 | 2019-2025 | Gattex |
| Sanofi-Aventis U.S. LLC | $103.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $101.29 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $90.14 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.